Synthesis of Bioactive Natural Products

生物活性天然产物的合成

基本信息

批准号：
7324105
负责人：
Amos B Smith
金额：
$ 27.97万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
1991
资助国家：
美国
起止时间：
1991-09-01 至 2010-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7324105
关键词：
13-deoxytedanolide 3-hydroxybutanal Acetylene Achievement Acids Acyl Coenzyme A Acylation Address Aldehydes Alkaloids Alkenes Alkylation Ally Anions Antibiotics Antineoplastic Agents Appendix Architecture Area Attention Aziridines Binding Biological Biological Factors Biomimetics Calcineurin Carbon Cell Line Chemicals Chemistry Cholesterol Clinical Cobalt Collaborations Complex Cyclization DNA Sequence Rearrangement Dental crowns Development Dimensions Dimethyl Sulfoxide Diterpenes Enzymes Epoxy Compounds Esters Evaluation Evolution FK506 Facility Construction Funding Category Family Felis catus Frustration Generations Goals Grant Hempa Human Hybrids Indoles Institutes Iodides Ions Japan Laboratories Licensing Macrolide Antibiotics Macrolides Marines Medical Medicine Methodology Methods Modeling Molecular Molecular Conformation Mus Nitrogen Object Attachment Octanes Outcome Oxygen Oxymetholone Paclitaxel Pharmacologic Substance Phase I Clinical Trials Porifera Preparation Productivity Progress Reports Protocols documentation Publications Rana Range Reaction Reader Relative (related person)Reporting Research Resistance Route Scheme Series Sirolimus Skeleton Solutions Staging Structure-Activity Relationship System Time Tokyo Transferase Treatment Protocols Tumor Cell Line Update Work Workplace analog antineoplastic antibiotics antitumor agent avermectin avermectins aziridine base callystatin A clinically relevant college concept demethoxyrapamycin design discodermolide dithiane experience flasks improved indole inhibitor/antagonist innovation kendomycin macrosphelide A macrosphelide B member milbemycin milbemycins mycoticin A n-butyllithium nodulisporic acid A nodulisporic acid D nodulisporic acid F novel octane oligomycin sensitivity-conferring protein oxidation penitrem D professor programs pyripyropene A rimocidin sorangicin A spirastrellolide A stereochemistry success targeted delivery tedanolide ylide

项目摘要

The principal goals for the 24-27 years update since July 2005 will now include: (A) development of an enantioselective total synthesis of the potent insecticidal agent (+)-nodulisporic acid A, (B) completion of the total synthesis of the challenging macrolide antibiotic (+)-sorangicin A; and (C) development of a viable enantioselective total synthesis of the architecturally complex marine antitumor macrolide spirastrellolide A. As in the past, each of these targets will require the development of as yet unforeseen new synthetic methodology to overcome unforeseen obstacles. This is indeed the excitement and frustration of target oriented total synthesis. In the area of new synthetic methods, we will: (D) develop the new modular indole synthesis comprising a sequential Stille and Buchwald-Hartwig cross-coupling union/cyclization tactic, devised in conjunction with the nodulisporic acid A synthetic venture; (E) expand and showcase the new concept of Anion Relay Chemistry (ARC), a powerful synthetic tactic introduced at the time of our previous renewal application, albeit without "proof of concept". Towards the latter end,we will explore a wide variety of nucleophiles, silyl linchpins possessing various anion stabilizing groups (ASG), and electrophiles to demonstrate the feasibility and rapid assembly of diverse, stereochemically complex oxygen and nitrogen substituted products in a single flask. Beyond these specific synthetic objectives, a general, long-range goal of this program is the identification of the molecular architecture responsible for biological activity. Thus, as we develop an approach to each target, we will also prepare model compounds designed to permit the elucidation of structure-activity relationships. Our experience with discodermolide gives us great confidence in this area.

自 2005 年 7 月以来的 24-27 年更新的主要目标现在包括： (A) 发展强效杀虫剂 (+)-节孢子酸 A 的对映选择性全合成，(B) 完成具有挑战性的大环内酯类抗生素(+)-sorangicin A的全合成； (C) 开发可行的结构复杂的海洋抗肿瘤大环内酯 spirastrellolide A 的对映选择性全合成。与过去一样，这些目标中的每一个都需要开发尚未预见到的新合成材料克服不可预见的障碍的方法。这确实是target的兴奋与无奈定向全合成。在新合成方法领域，我们将：（D）开发新的模块化吲哚合成方法包括连续的 Stille 和 Buchwald-Hartwig 交叉偶联联合/环化策略，设计于与球孢酸结合进行合成；（五）拓展和展示新理念阴离子中继化学 (ARC)，这是我们上次更新时引入的一种强大的合成策略应用程序，尽管没有“概念证明”。到最后，我们将探索各种各样的亲核试剂、具有各种阴离子稳定基团 (ASG) 的甲硅烷基关键和亲电子试剂展示多种立体化学复杂氧和氮的可行性和快速组装在一个烧瓶中的替代产品。除了这些具体的综合目标之外，该计划的一个总体长期目标是鉴定负责生物活性的分子结构。因此，当我们开发为了实现每个目标，我们还将准备模型化合物，旨在阐明结构-活性关系。我们在 discodermolide 方面的经验让我们对这一领域充满信心。